Abstract: Objective To investigate the clinical efficacy and safety of telbivudine on the prevention of mother-
to-child transmission of hepatitis B virus in late pregnancy. Methods Total of 200 cases with chronic hepatitis
B (CHB) in late pregnancy in Handan Infectious Disease Hospital from March 2012 to June 2015 were
enrolled and divided into experimental group and control group according to the time of admission, 100 cases
in each group. Patients in control group were given conventional treatment and patients in experimental group
were given telbivudine (600 mg, one time per day) on the basis of control group. After treated for 3 weeks and
6 weeks, the clinlcal symptom, development of ALT and adverse reactions in patients with different degree of
Hepatitis B between the two groups were compared. Results After 3 weeks and 6 weeks of treatment, there
were no significant differences in clinical symptoms between the two groups (P ＞ 0.05). After 3 weeks of
trial, the improvement rate of ALT in patients with mild hepatitis B in experimental group and control group
were 86.7% and 59.5%, respectively, the difference was statistically significant (χ 2 = 4.036，P = 0.040). The
improvement rate of ALT in patients with moderate and severe hepatitis B between experimental group and
control group had no significant differences after treated for 3 weeks and 6 weeks (P ＞ 0.05). There were no
serious adverse reactions in both groups, the difference had no statistical significance (χ 2 = 1.85, P = 0.45).
Conclusion Telbivudine had a certain effect on blocking the mother-to-child transmission in patients with
mild hepatitis B in late pregnancy.